Study reveals trigger that may speed melanoma growth

Study reveals trigger that may speed melanoma growth
Researchers identified molecule in tumors that suppresses immune system.

(HealthDay) -- Growth of the deadly skin cancer melanoma may be triggered by the immune system turning on itself, according to a new study that also identified the mechanism that causes this to happen.

Melanoma accounts for only about 5 percent of skin cancers, but is the cause of most skin cancer deaths, statistics indicate. The disease is often curable in its early stages but is difficult to treat once it has spread invasively, the authors of the new study noted.

The study, published in the current edition of the journal Science Translational Medicine, focused on a specific immune-inhibiting molecule called B7-H1 in melanoma tumors.

In patients with tumors that expressed B7-H1, suppression of the inflammatory immune response sped the growth and increased the aggressiveness of their tumors, the researchers from Yale School of Medicine and Johns Hopkins Medical Institutions found.

The investigators also found that tumor cells somehow use a component of the immune system itself (interferon gamma) to turn on B7-H1 and suppress the immune system.

"We were surprised to find that can not only escape or hide from infiltrating immune cells, but can go on the attack -- using as a weapon against the immune system," lead author Dr. Lieping Chen, a professor of immunobiology at Yale School of Medicine and director of the program at Yale Cancer Center, said in a Yale news release.

This mechanism may be responsible for and tumor growth in up to 40 percent of melanoma patients, Chen said. The finding may make it possible to develop therapies that block this immune-suppressing ability, he added.

More information: The American Cancer Society has more about melanoma.

Related Stories

Using Viagra to combat malignant melanoma

Nov 08, 2011

Many tumors cause chronic inflammations, which, in their turn, suppress specific attacks against the tumor by the immune system. Scientists at the German Cancer Research Center and Medical Faculty Mannheim ...

New combination therapy safe, promising for melanoma patients

Jun 01, 2008

The combination of two different biotherapies may be beneficial for patients with inoperable melanoma, according to a University of Pittsburgh Cancer Institute (UPCI) study presented at the 44th annual meeting of the American ...

Researchers building melanoma vaccine to combat skin cancer

Mar 19, 2012

Mayo Clinic researchers have trained mouse immune systems to eradicate skin cancer from within, using a genetic combination of human DNA from melanoma cells and a cousin of the rabies virus. The strategy, called cancer immunotherapy, ...

Study: Tumors inhibit immune system

May 29, 2006

Seattle scientists have shown that tumors can manipulate the immune system to stop it from attacking cancer cells, said a study published in Nature Immunology.

Recommended for you

US OKs first-ever DNA alternative to Pap smear (Update 2)

10 hours ago

U.S. government health regulators have cleared a genetic test from Roche as a first-choice screening option for cervical cancer. It was a role previously reserved for the Pap smear, the decades-old mainstay of women's health.

New breast cancer imaging method promising

16 hours ago

The new PAMmography method for imaging breast cancer developed by the University of Twente's MIRA research institute and the Medisch Spectrum Twente hospital appears to be a promising new method that could ...

Palliation is rarely a topic in studies on advanced cancer

16 hours ago

End-of-life aspects, the corresponding terminology, and the relevance of palliation in advanced cancer are often not considered in publications on randomized controlled trials (RCTs). This is the result of an analysis by ...

User comments